Eli Lilly and Company $LLY Stock: Fulcrum Asset Management LLP Boosts Holdings

Key Points

• Fulcrum Asset Management increased its Eli Lilly stake by 27.9% in the third quarter, to 11,093 shares valued at about $13.1 million. Institutional investors and hedge funds own 82.53% of the stock.
• Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $1,416.64, with 24 analysts rating the shares Buy.
• Lilly’s latest quarterly results beat expectations, with EPS of $7.48 versus $5.71 forecast and revenue of $24.4 billion, up 38.6% year over year. Shares were reported up 4.4% in Tuesday trading.

Fulcrum Asset Management LLP boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,093 shares of the company's stock after buying an additional 2,418 shares during the quarter. Eli Lilly and Company makes up approximately 0.6% of Fulcrum Asset Management LLP's portfolio, making the stock its 20th biggest position. Fulcrum Asset Management LLP's holdings in Eli Lilly and Company were worth $13,141,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Eli Lilly and Company by 5.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 330,482 shares of the company's stock valued at $380,005,000 after purchasing an additional 15,758 shares during the last quarter. rebel Financial LLC bought a new stake in Eli Lilly and Company during the third quarter valued at $234,000. StoneRidge PMG Advisors LLC bought a new stake in Eli Lilly and Company during the third quarter valued at $1,906,000. Beverly Hills Private Wealth LLC boosted its position in Eli Lilly and Company by 15.4% during the third quarter. Beverly Hills Private Wealth LLC now owns 1,147 shares of the company's stock valued at $1,326,000 after acquiring an additional 153 shares during the last quarter. Finally, Brickley Wealth Management grew its holdings in Eli Lilly and Company by 23.8% during the 3rd quarter. Brickley Wealth Management now owns 302 shares of the company's stock worth $349,000 after acquiring an additional 58 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research report on Monday, November 2nd. UBS Group upped their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research report on Friday, October 30th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Finally, TD Cowen reissued a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,416.64.

Insider Activity

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company's stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Eli Lilly and Company Trading Up 4.4%

Shares of Eli Lilly and Company stock opened at $1,413.22 on Tuesday. The stock has a fifty day simple moving average of $1,220.13 and a 200 day simple moving average of $1,102.83. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,453.00. The company has a market capitalization of $1.33 trillion, a P/E ratio of 45.87, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter last year, the company posted $7.02 EPS. The business's quarterly revenue was up 38.6% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.